Cerus Co. (NASDAQ:CERS) CEO Sells $91,476.00 in Stock

Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 60,984 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $1.50, for a total transaction of $91,476.00. Following the sale, the chief executive officer now owns 4,309,758 shares of the company’s stock, valued at approximately $6,464,637. This represents a 1.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

William Mariner Greenman also recently made the following trade(s):

• On Tuesday, March 4th, William Mariner Greenman sold 23,023 shares of Cerus stock. The shares were sold at an average price of $1.55, for a total transaction of $35,685.65.

Cerus Trading Down 0.7 %

NASDAQ CERS opened at $1.48 on Thursday. Cerus Co. has a 12 month low of $1.38 and a 12 month high of $2.54. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The company has a market capitalization of $274.97 million, a price-to-earnings ratio of -13.45 and a beta of 1.56. The company’s fifty day moving average price is $1.73 and its two-hundred day moving average price is $1.78.

Cerus (NASDAQ:CERS) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $50.81 million for the quarter, compared to analysts’ expectations of $50.81 million. Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. As a group, research analysts predict that Cerus Co. will post -0.08 earnings per share for the current fiscal year.

Institutional Trading of Cerus

Large investors have recently modified their holdings of the company. Rockport Wealth LLC acquired a new stake in shares of Cerus in the 4th quarter worth about $25,000. Cibc World Markets Corp acquired a new position in Cerus during the 4th quarter valued at about $26,000. R Squared Ltd bought a new position in shares of Cerus during the 4th quarter valued at about $29,000. Virtu Financial LLC bought a new position in shares of Cerus during the 4th quarter valued at about $33,000. Finally, Dark Forest Capital Management LP bought a new position in shares of Cerus during the 4th quarter valued at about $34,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 target price on shares of Cerus in a research note on Friday, February 21st.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.